Logo image of BRTX

BIORESTORATIVE THERAPIES INC (BRTX) Stock Fundamental Analysis

NASDAQ:BRTX - Nasdaq - US0906556065 - Common Stock - Currency: USD

1.7088  +0.07 (+4.2%)

After market: 1.66 -0.05 (-2.86%)

Fundamental Rating

4

BRTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While BRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. BRTX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BRTX had negative earnings in the past year.
BRTX had a negative operating cash flow in the past year.
In the past 5 years BRTX always reported negative net income.
BRTX had a negative operating cash flow in each of the past 5 years.
BRTX Yearly Net Income VS EBIT VS OCF VS FCFBRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of BRTX (-117.13%) is worse than 80.29% of its industry peers.
With a Return On Equity value of -196.85%, BRTX is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -117.13%
ROE -196.85%
ROIC N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRTX Yearly ROA, ROE, ROICBRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Gross Margin of BRTX (92.10%) is better than 93.37% of its industry peers.
The Profit Margin and Operating Margin are not available for BRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRTX Yearly Profit, Operating, Gross MarginsBRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BRTX has been increased compared to 5 years ago.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRTX Yearly Shares OutstandingBRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BRTX Yearly Total Debt VS Total AssetsBRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -23.27, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
BRTX has a Altman-Z score of -23.27. This is amonst the worse of the industry: BRTX underperforms 87.46% of its industry peers.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.27
ROIC/WACCN/A
WACC8.98%
BRTX Yearly LT Debt VS Equity VS FCFBRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.24 indicates that BRTX has no problem at all paying its short term obligations.
The Current ratio of BRTX (2.24) is worse than 72.94% of its industry peers.
BRTX has a Quick Ratio of 2.24. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.24, BRTX is doing worse than 71.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
BRTX Yearly Current Assets VS Current LiabilitesBRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.47% over the past year.
BRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 170.96%.
The Revenue has been growing by 25.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.94%
Revenue 1Y (TTM)170.96%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-28.57%

3.2 Future

The Earnings Per Share is expected to grow by 48.76% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRTX will show a very strong growth in Revenue. The Revenue will grow by 207.13% on average per year.
EPS Next Y-40.21%
EPS Next 2Y3.5%
EPS Next 3Y45.12%
EPS Next 5Y48.76%
Revenue Next Year131.98%
Revenue Next 2Y54.95%
Revenue Next 3Y288.05%
Revenue Next 5Y207.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BRTX Yearly Revenue VS EstimatesBRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BRTX Yearly EPS VS EstimatesBRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRTX Price Earnings VS Forward Price EarningsBRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRTX Per share dataBRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as BRTX's earnings are expected to grow with 45.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.5%
EPS Next 3Y45.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORESTORATIVE THERAPIES INC

NASDAQ:BRTX (6/24/2025, 8:19:19 PM)

After market: 1.66 -0.05 (-2.86%)

1.7088

+0.07 (+4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners12.62%
Inst Owner Change0.12%
Ins Owners25.54%
Ins Owner Change0%
Market Cap12.82M
Analysts82.5
Price Target13.26 (675.98%)
Short Float %2.54%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.18%
Min EPS beat(2)-93.06%
Max EPS beat(2)28.7%
EPS beat(4)3
Avg EPS beat(4)4.39%
Min EPS beat(4)-93.06%
Max EPS beat(4)69.45%
EPS beat(8)7
Avg EPS beat(8)14.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-92.31%
Min Revenue beat(2)-93.55%
Max Revenue beat(2)-91.06%
Revenue beat(4)1
Avg Revenue beat(4)65.66%
Min Revenue beat(4)-93.55%
Max Revenue beat(4)481.7%
Revenue beat(8)5
Avg Revenue beat(8)92.59%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-90%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.03%
Revenue NY rev (1m)-10.12%
Revenue NY rev (3m)-25.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.78
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.31
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.05
BVpS0.82
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.13%
ROE -196.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.1%
FCFM N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -23.27
F-Score4
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.94%
EPS Next Y-40.21%
EPS Next 2Y3.5%
EPS Next 3Y45.12%
EPS Next 5Y48.76%
Revenue 1Y (TTM)170.96%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-28.57%
Revenue Next Year131.98%
Revenue Next 2Y54.95%
Revenue Next 3Y288.05%
Revenue Next 5Y207.13%
EBIT growth 1Y9.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.09%
OCF growth 3YN/A
OCF growth 5YN/A